Finding · criterion S5

Who calls a peptide pharmaceutical grade, and what does the term require?

18 of the 201 sellers read for the phrase call their product pharmaceutical grade, and 11 say it is made under good manufacturing practice. 9 of the 44 research vendors read make one claim or the other while labeling the same product for research use only. FDA does not define pharmaceutical grade.

The number, with its denominator

The count covers 201 ledger records whose own pages were read in September 2026: 157 telehealth services and 44 research vendors. On each, the home page, the product pages and the pages that describe quality or sourcing were read. A phrase counts only where it appears in the text a visitor sees and describes the seller's own product or process. A sentence advising readers to look for pharmaceutical grade elsewhere is not counted, and neither is a solvent or a diluent described that way.

What the term requires

No FDA page defines pharmaceutical grade. FDA uses the words once in its guidance on insanitary conditions at compounding facilities, beside the word compendial, without a definition: Using active ingredients, inactive ingredients, or processing aides, that have or may have higher levels of impurities compared to compendial or pharmaceutical grade equivalents The standards that do bind a drug are two. The compendium: a drug named in the United States Pharmacopeia is adulterated under FD&C Act section 501(b), 21 U.S.C. 351(b) If it purports to be or is represented as a drug the name of which is recognized in an official compendium, and its strength differs from, or its quality or purity falls below, the standard set forth in such compendium. And manufacturing practice, which 21 CFR 210.1 describes as The regulations set forth in this part and in parts 211, 213, 225, and 226 of this chapter contain the minimum current good manufacturing practice for methods to be used in, and the facilities or controls to be used for, the manufacture, processing, packing, or holding of a drug to assure that such drug meets the requirements of the act as to safety, and has the identity and strength and meets the quality and purity characteristics that it purports or is represented to possess.

A 503A pharmacy compounding for a patient must also buy its ingredient from a registered establishment with a certificate of analysis, under FD&C Act section 503A(b)(1)(A), 21 U.S.C. 353a: (ii) that are manufactured by an establishment that is registered under section 360 of this title (including a foreign establishment that is registered under section 360(i) of this title); and (iii) that are accompanied by valid certificates of analysis for each bulk drug substance;

What the telehealth services say

What the research vendors say

9 research vendors print a grade or manufacturing claim on the same site that labels its products for laboratory research only. The label and the claim sit together on the page. Grade and manufacturing practice are standards for a drug made for people; a product sold as not for human use disclaims the use they exist for.

Prosecutors have quoted the same kind of claim back. The Department of Justice release on the Paradigm Peptides sentencing says the company represented that its products were safe and of pharmaceutical quality. That case is on the page about enforcement past a warning letter.

How the Standard reads the claim

A grade claim satisfies no criterion by itself. S5 asks for a document a reader can check: a certificate of analysis naming the lot, the laboratory and the method. S4 asks a telehealth service to say that a compounded drug is compounded and not FDA-approved. See S5 and S4.

Sources

Seller pages and regulations were read in September 2026. Counts are computed at build time against Standard v1.1.

Counts are generated from the ledger at build time, so this page cannot drift from the records it summarizes. Method and null semantics: how checks are performed. This page ranks nothing, recommends nothing, and carries no partner link.

Which laboratories sign the research vendors' test reports?A handful of laboratories sign most of the reports, few of them state an accreditation on their own sites, and some vendors credit a laboratory on the homepage that signs none of their documents.

The state of the Standard, edition 1Eight criteria applied to every record, each reported as its own pass, fail and not-verified count, split between telehealth services and research vendors. No criterion is summed with another, and no record is scored.

The criterion the licensed services fail and the research vendors passAlmost the whole split runs one way. The sellers operating outside the prescription system publish more laboratory evidence than the licensed services do, with exceptions on both sides named on the page. The split is structural rather than a difference in care, and a certificate is a document about one lot, not an approval.

Who sells retatrutide, a drug still in phase 3 trials?Research vendors sell it, labeled for laboratory use, several of them under a code rather than its name, while the maker has not filed it for approval and FDA states that it cannot be used in compounding.

All 19 findings →